New study challenges classic tenet of memory research

Connections among one set of activated neurons in rat brains grew stronger while memories were being formed, but those in another weakened, UT Southwestern Medical Center researchers have discovered. The findings, at odds with traditional thinking about how the brain operates, provide clues into the mystery of learning and memory, processes that go awry in diseases including Alzheimer’s, schizophrenia, and autism.

Global background rates study analyzes data from 197 million people for assessment of COVID-19 vaccine safety

The U.S. CDC (Centers for Disease Control and Prevention) Global COVID Vaccine Safety Project has generated background incidence rates on a range of conditions designated as AESI (Adverse Events of Special Interest) for COVID-19 vaccine safety monitoring. Conditions studied included myocarditis, pulmonary embolism, and Guillain-Barré syndrome.

‘DOWN, NOT OUT’

…Muza coach Mathews Ndlovu still confident 

By MICHAEL MIYOBA 

FC Muza coach Mathews Ndlovu is confident that the Zambian envoys in the CAF Confederations Cup are not out despite a 2-1 home loss yesterday to Congo Brazzaville giants Diables Noir in the first leg second preliminary match played at Heroes Stadium in Lusaka. 

This content is locked

This is exclusive material. To read full story, click on register and choose one of the premium subscriptions to view this content. Login if you are already a premium user.


Research team leads adaptive, efficient multi-arm phase 2 clinical trial for glioblastoma

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute, in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma, has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.

Researchers discover possible new treatment for triple-negative breast cancer

Zachary Schug, Ph.D., assistant professor in the Molecular and Cellular Oncogenesis Program of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute, has published a new paper in the journal Nature Cancer. Schug’s paper, titled “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer,” demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer. Schug’s research shows how silencing a certain gene, ACSS2, may improve existing treatments for patients.